4月15日,映恩生物在中国香港上市首日股价上涨130%,总市值达到约180亿港元。该公司在IPO中筹集了15.55亿港元,也成为港股市场自2022年以来规模最大的18A生物科技IPO。映恩生物的招股书显示,该公司正在开发用于治疗癌症和自身免疫性疾病的药物。早在2023年,BioNTech就与映恩生物达成了3个抗体偶联药物(ADC)的合作开发,总金额超过20亿美元。截至目前,映恩生物累计对外授权交易...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.